| Mechanisms of resistance to crizotinib in patients with ALK gene rearranged non–small cell lung cancer RC Doebele, AB Pilling, DL Aisner, TG Kutateladze, AT Le, AJ Weickhardt, ... Clinical cancer research 18 (5), 1472-1482, 2012 | 1277 | 2012 |
| Local ablative therapy of oligoprogressive disease prolongs disease control by tyrosine kinase inhibitors in oncogene-addicted non–small-cell lung cancer AJ Weickhardt, B Scheier, JM Burke, G Gan, X Lu, PA Bunn Jr, DL Aisner, ... Journal of Thoracic Oncology 7 (12), 1807-1814, 2012 | 710 | 2012 |
| [177Lu] Lu-PSMA-617 versus cabazitaxel in patients with metastatic castration-resistant prostate cancer (TheraP): a randomised, open-label, phase 2 trial MS Hofman, L Emmett, S Sandhu, A Iravani, AM Joshua, JC Goh, ... The Lancet 397 (10276), 797-804, 2021 | 613 | 2021 |
| Oncogene status predicts patterns of metastatic spread in treatment‐naive nonsmall cell lung cancer RC Doebele, X Lu, C Sumey, DLA Maxson, AJ Weickhardt, AB Oton, ... Cancer 118 (18), 4502-4511, 2012 | 305 | 2012 |
| Impact of KRAS and BRAF gene mutation status on outcomes from the phase III AGITG MAX trial of capecitabine alone or in combination with bevacizumab and mitomycin in advanced … TJ Price, JE Hardingham, CK Lee, A Weickhardt, AR Townsend, JW Wrin, ... J Clin Oncol 29 (19), 2675-2682, 2011 | 250 | 2011 |
| Ablative Local Therapy Extends the Clinical Benefit of Crizotinib in Alk-positive Lung Cancer GN Gan, DR Camidge, AJ Weickhardt, RC Doebele, W Dzingle, B Scheier, ... International Journal of Radiation Oncology, Biology, Physics 84 (3), S67-S68, 2012 | 197* | 2012 |
| ROS1 and ALK Fusions in Colorectal Cancer, with Evidence of Intratumoral Heterogeneity for Molecular Drivers DL Aisner, TT Nguyen, DD Paskulin, AT Le, J Haney, N Schulte, F Chionh, ... Molecular Cancer Research 12 (1), 111-118, 2014 | 132 | 2014 |
| Dual targeting of the epidermal growth factor receptor using the combination of cetuximab and erlotinib: preclinical evaluation and results of the phase II DUX study in … AJ Weickhardt, TJ Price, G Chong, V Gebski, N Pavlakis, TG Johns, ... Journal of clinical oncology 30 (13), 1505-1512, 2012 | 118 | 2012 |
| Rapid‐onset hypogonadism secondary to crizotinib use in men with metastatic nonsmall cell lung cancer AJ Weickhardt, MS Rothman, S Salian‐Mehta, K Kiseljak‐Vassiliades, ... Cancer 118 (21), 5302-5309, 2012 | 109 | 2012 |
| Diagnostic assays for identification of anaplastic lymphoma kinase‐positive non–small cell lung cancer AJ Weickhardt, DL Aisner, WA Franklin, M Varella‐Garcia, RC Doebele, ... Cancer 119 (8), 1467-1477, 2013 | 98 | 2013 |
| Phase I/II study of the LAG-3 inhibitor ieramilimab (LAG525)±anti-PD-1 spartalizumab (PDR001) in patients with advanced malignancies P Schöffski, DSW Tan, M Martín, M Ochoa-de-Olza, J Sarantopoulos, ... Journal for immunotherapy of cancer 10 (2), 2022 | 89 | 2022 |
| Oxaliplatin-Induced Neuropathy in Colorectal Cancer A Weickhardt, K Wells, W Messersmith Journal of Oncology 2011, 2011 | 83 | 2011 |
| Prospective, multisite, international comparison of 18F-fluoromethylcholine PET/CT, multiparametric MRI, and 68Ga-HBED-CC PSMA-11 PET/CT in men with high-risk features and … L Emmett, U Metser, G Bauman, RJ Hicks, A Weickhardt, ID Davis, ... Journal of Nuclear Medicine 60 (6), 794-800, 2019 | 82 | 2019 |
| Drug‐induced reduction in estimated glomerular filtration rate in patients with ALK‐positive non‐small cell lung cancer treated with the ALK inhibitor crizotinib EM Brosnan, AJ Weickhardt, X Lu, DA Maxon, AE Barón, M Chonchol, ... Cancer 120 (5), 664-674, 2014 | 77 | 2014 |
| Phase I/II study of LAG525±spartalizumab (PDR001) in patients (pts) with advanced malignancies. DS Hong, P Schoffski, A Calvo, J Sarantopoulos, M Ochoa De Olza, ... Journal of Clinical Oncology 36 (15_suppl), 3012-3012, 2018 | 70 | 2018 |
| Vascular endothelial growth factor D expression is a potential biomarker of bevacizumab benefit in colorectal cancer AJ Weickhardt, DS Williams, CK Lee, F Chionh, J Simes, C Murone, ... British journal of cancer 113 (1), 37-45, 2015 | 70 | 2015 |
| Radiotherapy and immunotherapy: a synergistic effect in cancer care GA Turgeon, A Weickhardt, AA Azad, B Solomon, S Siva The Medical Journal of Australia 210 (1), 47-53, 2019 | 68 | 2019 |
| Vascular endothelial growth factors (VEGF) and VEGF receptor expression as predictive biomarkers for benefit with bevacizumab in metastatic colorectal cancer (mCRC): Analysis … AJ Weickhardt, D Williams, C Lee, J Simes, C Murone, K Wilson, ... Journal of Clinical Oncology 29 (15_suppl), 3531-3531, 2011 | 66 | 2011 |
| Dual checkpoint targeting of B7-H3 and PD-1 with enoblituzumab and pembrolizumab in advanced solid tumors: interim results from a multicenter phase I/II trial C Aggarwal, A Prawira, S Antonia, O Rahma, A Tolcher, RB Cohen, Y Lou, ... Journal for immunotherapy of cancer 10 (4), 2022 | 64 | 2022 |
| A phase I/II study of erlotinib in combination with the anti-insulin-like growth factor-1 receptor monoclonal antibody IMC-A12 (cixutumumab) in patients with advanced non-small … A Weickhardt, R Doebele, A Oton, J Lettieri, DL Maxson, M Reynolds, ... Journal of Thoracic Oncology 7 (2), 419-426, 2012 | 64 | 2012 |
Ross CamidgeVerified email at cuanschutz.edu
